{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:08:27Z","timestamp":1790212107544,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Decis Making"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:p>Background. This study reports incremental cost-utility of sibutramine compared to diet and lifestyle advice for the treatment of obesity. Method. The model estimates the costs and quality of life benefits associated with weight loss itself and the reduced incidence of coronary heart disease (CHD) and diabetes in the \u201chealthy obese.\u201d The key source of effectiveness data is 2 randomized controlled trials over 12 months. Utility gain per kilogram lost is analyzed using Short Form\u201336 data from sibutramine trials. The impact on CHD is estimated using the Framingham risk equation, which relates age\/sex\/body mass index to risk of heart disease. The reduced incidence of diabetes due to weight loss is estimated from published literature. A life tables approach was used to calculate the cost per quality-adjusted life year (QALY) of 1 year\u2019s treatment with sibutramine compared to diet and lifestyle advice. Results. The incremental cost per QALY of sibutramine is \u00a34780. Sensitivity analyses show that this result is sensitive to utility associated with weight loss and the frequency of monitoring.Conclusions. Sibutramine is a costeffective treatment for obesity when combined with diet and lifestyle advice.<\/jats:p>","DOI":"10.1177\/0272989x03261565","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T21:01:24Z","timestamp":1082581284000},"page":"9-19","source":"Crossref","is-referenced-by-count":26,"title":["Cost-Effectiveness of Sibutramine in the Treatment of Obesity"],"prefix":"10.1177","volume":"24","author":[{"given":"Emma","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brennan","sequence":"additional","affiliation":[{"name":"Operational Research, ScHARR, 30 Regent Street, Sheffield, S1 4DA, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Akehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2004,1,1]]},"reference":[{"key":"atypb1","unstructured":"1. Department of Health. Health Survey for England 1998, Cardiovascular Disease. Available from: http:\/\/www.official-documents.co.uk\/document\/doh\/survey98\/hse98.htm."},{"key":"atypb2","unstructured":"2. West R. Obesity. London: London Office for Health Economics; 1994."},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.9.961"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-7-199504010-00001"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117386"},{"key":"atypb6","unstructured":"6. Smith IG, Goulder MA. Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505\u2013512."},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"atypb8","unstructured":"8. SmPC. Reductil, summary of product characteristics. Available from: www.emea.eu.int\/index.htm."},{"key":"atypb9","unstructured":"9. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomised trials of sibutramine versus placebo. Am J Managed Care. 2001;7(9):875\u2013883."},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801035"},{"key":"atypb11","unstructured":"11. British National Formulary. British National Formulary 43; 2002. Available from: www.bnf.org.uk."},{"key":"atypb12","unstructured":"12. Netten A, Dennett J. Unit Costs of Health and Social Care 1998. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 1998."},{"key":"atypb13","unstructured":"13. Department of Health. Financial Matters, Appendix 1, Health Service Cost Index. London: Department of Health; 2000."},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"14. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Am Heart Anderson Med\/Sci Statement. 1991;83(1):356\u2013363.","DOI":"10.1161\/01.CIR.83.1.356"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.80.1.40"},{"key":"atypb16","unstructured":"16. Government Actuary Department. England andWales life tables. Available from: http:\/\/www.gad.gov.uk\/."},{"key":"atypb17","unstructured":"17. Centers for Disease Control and Prevention. National Vital Statistics Report. United States Life Tables. Atlanta (GA): Centers for Disease Control and Prevention; 1998."},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7133.736"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.5.957"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.82.3.325"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00136-2"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00436.x"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.8.1266"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.11.1828"},{"key":"atypb25","doi-asserted-by":"crossref","unstructured":"25. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss andmortality in overweight whitemen aged 40-64 years. Am J Epidemiol. 1999;146(6):491\u2013503.","DOI":"10.1093\/oxfordjournals.aje.a009843"},{"key":"atypb26","unstructured":"26. De Grauw WJC, Van Den Hoogen HJM, Van De Lisdonk EH, Van Gerwen WHEM, Van Weel C. Control group characteristics and study outcomes: empirical data from a study on mortality of patients with type 2 diabetes mellitus in Dutch general practice. J Epidemiol Community Health. 1998;52(Suppl 1):9s\u201312s."},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.3111\/199902143153"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.2.151"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00103-6"},{"key":"atypb30","unstructured":"30. MAG Mutual Healthcare Solutions. Physicians Fee and Coding Guide. Duluth (GA); MAG Mutual Healthcare Solutions; 2000."},{"key":"atypb31","unstructured":"31. Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be towarrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146(4):473\u2013481."},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802026"}],"container-title":["Medical Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X03261565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X03261565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:51:34Z","timestamp":1777657894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0272989X03261565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1177\/0272989X03261565"],"URL":"https:\/\/doi.org\/10.1177\/0272989x03261565","relation":{},"ISSN":["0272-989X","1552-681X"],"issn-type":[{"value":"0272-989X","type":"print"},{"value":"1552-681X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}